共 50 条
- [41] Impact of induction therapy with 3 doses of infliximab on deep remission in paediatric patients with active Crohn's DiseaseJOURNAL OF CROHNS & COLITIS, 2015, 9 : S222 - S222Szymanska, E.Dadalski, M.Szymanska, S.Grajkowska, W.Pronicki, M.Kierkus, J.
- [42] Rapid symptomatic improvement with subcutaneous infliximab induction treatment for patients with moderate-to-severe Crohn's disease: first results from the DIRECT-CD studyJOURNAL OF CROHNS & COLITIS, 2024, 18 : I1682 - I1683Anjie, S.Jharap, B.Jansen, J. M.Mares, W. G.Duijvestein, M.Maljaars, J. P. W.Oldenburg, B.D'Haens, G. R. A. M.Gecse, K. B.
- [43] Induction and Maintenance Adalimumab Therapy for the Treatment of Moderate to Severe Crohn's Disease in ChildrenGASTROENTEROLOGY, 2011, 140 (05) : S90 - S90Hyams, Jeffrey S.Griffiths, Anne M.Markowitz, JamesBaldassano, RobertFaubion, William A.Colletti, Richard B.Dubinsky, MariaKierkus, JaroslawWang, YaqinHuang, BidanBittle, BarryMarshall, MichaelLazar, Andreas
- [44] Maintenance therapy with infliximab every 8 weeks is superior to every 12 weeks in maintaining response and remission in pediatric patients with moderately to severely active Crohn's diseaseGASTROENTEROLOGY, 2006, 130 (04) : A12 - A12Hyams, JeffreyCrandall, WallaceKugathasan, SubiaGriffiths, AnneOlson, AllanJohanns, JewelLiu, GraceTravers, SuzanneHeuschkel, RobertMarkowitz, JamesCohen, StanleyWinter, HarlandVeereman-Wauters, GigiFerry, GeorgeBaldassano, Robert
- [45] Baseline and Early Predictors of Response to Risankizumab Induction and Maintenance Treatment in Patients With Moderate to Severe Crohn's DiseaseAMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S594 - S595Colombel, Jean-FredericReinisch, WalterSchreiber, StefanDanese, SilvioSugimoto, KenAbreu, Maria T.Martin, NaomiKligys, KristinaPivorunas, ValerieSong, AlexandraZambrano, JavierZhang, YafeiPanaccione, Remo
- [46] A PHASE 3 STUDY OF VEDOLIZUMAB FOR INDUCTION AND MAINTENANCE THERAPY IN JAPANESE PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASEGASTROENTEROLOGY, 2019, 156 (06) : S1109 - S1109Ogata, HaruhikoMotoya, SatoshiWatanabe, KenjiKanai, TakanoriMatsui, ToshiyukiSuzuki, YasuoShikamura, MitsuhiroSugiura, KenkichiOda, KazunoriHori, TetsuharuAraki, TakahiroWatanabe, MamoruHibi, Toshifumi
- [47] Mirikizumab Pharmacokinetics and Exposure-Response in a Phase 2 Study in Patients With Moderately to Severely Active Crohn's DiseaseJOURNAL OF CROHNS & COLITIS, 2024, 18 : I1873 - I1873Chua, L.Otani, Y.Friedrich, S.Durand, F.Zhang, X.
- [48] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE IN A PHASE 2 STUDY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASEGASTROENTEROLOGY, 2024, 166 (05) : S822 - S822Chua, LaiyiOtani, YukiFriedrich, StuartDurand, FrederickZhang, Xin
- [49] Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to InfliximabCLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (08) : 688 - 695Sandborn, William J.Abreu, Maria T.D'Haens, GeertColombel, Jean-FredericVermeire, SeverineMitchev, KrassimirJamoul, CorinneFedorak, Richard N.Spehlmann, Martina E.Wolf, Douglas C.Lee, ScottRutgeerts, Paul
- [50] Super-responders in patients with moderate-to-severe Crohn's disease treated with subcutaneous infliximab maintenance therapy: A post hoc analysis of the LIBERTY-CD studyJOURNAL OF CROHNS & COLITIS, 2024, 18 : I1365 - I1366Schreiber, S. W.Sands, B. E.Hanauer, S. B.Danese, S.Loftus, E. V., Jr.Jeong, A. L.Kim, D. H.Lee, Y. N.Colombel, J. F.